Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of mRNA-1345 RSV vaccine in pregnant women and their infants
jRCT2031230752Phase 2Active, not recruiting
- Sponsor
- Moderna Inc
- Start
- Sep 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, randomised, single-blind trial of RNA-100-AR02 in respiratory syncytial virus disease (RSV) (4 arms), sponsored by Moderna Inc. Primary endpoints: Number of maternal participants with solicited local and systemic adverse reactions, Number of maternal participants with unsolicited adverse events and 9 more. Started Sep 2024; status: active, not recruiting.
02
Drugs
RNA-100-AR02
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2031230752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230752.